| Effect | None |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 160 |
| Sex | Both Genders |
In a 6-week randomized, double-blind, placebo-controlled trial, 160 participants with multiple sclerosis took Sativex which contains 2.7 mg of THC and 2.5 mg of CBD per 100 ul spray, and were urged to titrate up slowly and to not exceed 120 mg of THC per day and no more than 20 mg in a 3 hour period.Funding issues for this study:
The primary outcome was a visual analog scale score for each patient's most troublesome symptom. There was a greater improvement in the cannabis group placebo but the difference wasn't statistically significant. There was a statistically significant improvement in spasticity, Barthel ADL index, and sleep quality overall. For participants who had various primary symptoms, there was a statistically significant improvement in spasticity, but not the others, though there were general improvements. The placebo group actually saw a greater reduction in pain, though it wasn't statistically significant.
GW Pharma Ltd contributed to the study design and was
involved in collection of the data. Data handling and
analysis were contracted by GW Pharma Ltd to an
independent research organization.
